A Clinical Trial Collecting Data From Routine Ophthalmological Examinations of Patients Who Were Randomized to Either Finerenone or Placebo in the Two Bayer-sponsored Phase 3 Clinical Trials FIDELIO-DKD and FIGARO-DKD to Investigate the Effect of Finerenone on Delaying the Progression of Diabetic Retinopathy
Latest Information Update: 05 Jul 2022
At a glance
- Drugs Finerenone (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms DeFineDR
- Sponsors Bayer
- 14 Jul 2021 Status changed from recruiting to completed.
- 06 May 2021 Status changed from not yet recruiting to recruiting.
- 17 Mar 2021 New trial record